About Neurotech International
Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical company focused on the development and commercialisation of NTI164, an oral cannabinoid drug therapy for paediatric neurological disorders. The company has completed multiple clinical trials demonstrating significant benefits in conditions such as Autism Spectrum Disorder (ASD), PANDAS/PANS, and Rett Syndrome, and is advancing further clinical research including in spastic cerebral palsy.